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Objectives. This study sought to evaluate the incidence of ocular
hemorrhage in patients with and without diabetes after thrombo-
lytic therapy for acute myocardial infarction.
Background. Ocular hemorrhage after thrombolysis has been
reported rarely. However, there is concern that the risk is
increased in patients with diabetes. In fact, diabetic hemorrhagic
retinopathy has been identified as a contraindication to thrombo-
lytic therapy without clear evidence that these patients have an
increased risk for ocular hemorrhage.
Methods. We identified all suspected ocular hemorrhages from
bleeding complications reported in patients enrolled in the Global
Utilization of Streptokinase and t-PA for Occluded Coronary
Arteries (GUSTO)-I trial. Additional information was collected on
a one-page data form. We compared the incidence and location of
ocular hemorrhages in patients with and without diabetes.
Results. There were 40,899 patients (99.7%) with information
about diabetic history and ocular bleeding. Twelve patients
(0.03%) had an ocular hemorrhage. Intraocular hemorrhage was
confirmed in only one patient. There were 6,011 patients (15%)
with diabetes, of whom only 1 had an ocular hemorrhage (eyelid
hematoma after a documented fall). The upper 95% confidence
intervals for the incidence of intraocular hemorrhage in patients
with and without diabetes were 0.05% and 0.006%, respectively.
Conclusions. Ocular hemorrhage and, more important, intraoc-
ular hemorrhage after thrombolytic therapy for acute myocardial
infarction is extremely uncommon. The calculated upper 95%
confidence interval for the incidence of intraocular hemorrhage in
patients with diabetes was only 0.05%. We conclude that diabetic
retinopathy should not be considered a contraindication to throm-
bolysis in patients with an acute myocardial infarction.
(J Am Coll Cardiol 1997;30:1606–10)
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Diabetic hemorrhagic retinopathy has been classified as an
absolute contraindication to thrombolytic therapy in patients
with acute myocardial infarction because of the risk of retinal
hemorrhage (1). It is listed as a relative contraindication to
alteplase (Genentech, Inc.) and to streptokinase (KabiVitrum,
Inc.) on package inserts. However, there is no clear evidence
that patients with diabetic retinopathy are at an increased risk
for intraocular hemorrhage after thrombolytic therapy. We
have found only two published case reports of patients with
intraocular hemorrhage associated with thrombolysis—one of
these patients had a history of diabetes, the other did not (2,3).
To better define the incidence and location of ocular
hemorrhage in patients with and without diabetes treated with
thrombolytic therapy for acute myocardial infarction, we ana-
lyzed the patients with ocular hemorrhage in the Global
Utilization of Streptokinase and t-PA for Occluded Coronary
Arteries (GUSTO)-I trial (4).
Methods
Study population. The study population was the 41,021
patients enrolled in the GUSTO-I trial (4). Patients were
enrolled at 1,081 centers in 15 countries between December
1990 and February 1993. In brief, patients presenting with an
acute myocardial infarction within 6 h of symptom onset were
randomized to one of four thrombolytic strategies: 1) strep-
tokinase, 1.5 million U, intravenously over 60 min and subcu-
taneous heparin, 12,500 U, twice daily; 2) streptokinase, 1.5
million U, intravenously over 60 min and intravenous heparin,
5,000 U bolus followed by 1,000 U/h; 3) alteplase in an
accelerated regimen (15-mg intravenous bolus followed by
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0.75 mg/kg body weight over 30 min, then 0.5 mg/kg over the
next 60 min) and intravenous heparin, 5,000 U bolus followed
by 1,000 U/h; or 4) both streptokinase, 1 million U, and
alteplase, 1.0 mg/kg over 60 min, and intravenous heparin,
5,000 U bolus followed by 1,000 U/h. All patients received
aspirin (160 to 325 mg) daily.
Patients were excluded from enrollment if there was active
bleeding, a history of previous stroke, previous treatment with
streptokinase or alteplase, recent trauma or major operation,
previous participation in the trial or recent noncompressible
vascular puncture. Patients with severe, uncontrolled hyperten-
sion (systolic blood pressure $180 mm Hg unresponsive to
therapy) were considered to have a relative contraindication to
enrollment. Patients with diabetes mellitus or diabetic compli-
cations were not excluded by the protocol.
Data collection. Case report forms were completed by
study coordinators at each site, reviewed by the principal
investigator and submitted to the GUSTO-I Coordinating
Center. The case report form collected information about
patient baseline clinical and historical characteristics, medica-
tions, procedures and clinical events and complications, includ-
ing bleeding with severity and location. Diabetic history,
including the age at diagnosis and whether there was a history
of insulin therapy, was also collected. A patient was defined as
having diabetes mellitus if a physician had made a diagnosis of
diabetes mellitus before or during the hospital period for the
acute myocardial infarction that resulted in enrollment in the
GUSTO-I trial.
Supplemental ocular hemorrhage form. For all patients
identified on the case report form as having an ocular hemor-
rhage, a supplemental form was sent to the study coordinator
at the site where the patient was enrolled. This form requested
additional information about the timing of the ocular hemor-
rhage in relation to the administration of thrombolytic therapy,
the location of the ocular hemorrhage, the presence of diabetic
complications, including previous diagnosis of diabetic retinop-
athy, and history of other ocular disease. If the patient was
seen by an ophthalmologist, a copy of the consultation note
was requested. In addition, information about suspected ocular
hemorrhage was collected by direct contact with study coordi-
nators or principal investigators at the site.
Statistical analysis. Clinical and historical data are re-
ported using percentages for categoric variables and 25th, 50th
and 75th percentiles for continuous variables. We used odds
ratios and 95% confidence intervals to compare the incidence
of ocular hemorrhage in patients with and without diabetes.
The logit estimators for the odds ratio and 95% confidence
intervals used a correction of 0.5 in every cell that contained
zero. Upper 95% confidence limits for the incidence of intraoc-
ular hemorrhage were estimated using the formula of Hanley
and Lippman-Hand (5).
Results
There were 41,021 patients enrolled in the GUSTO-I trial.
Data on diabetic history and ocular bleeding during the trial
were known for 40,899 patients (99.7%). The baseline clinical
characteristics for patients with and without ocular hemor-
rhage are shown in Table 1.
Twelve patients (0.03%) had an ocular hemorrhage in the
GUSTO-I trial. These hemorrhages included 11 extraocular
hemorrhages and only 1 confirmed intraocular (subretinal)
hemorrhage. The rate of intraocular hemorrhage was 0.002%
(1 of 40,889). Ocular hemorrhage location in patients with and
without diabetes is shown in Table 2. There was no difference
in the rate of ocular hemorrhage in patients with diabetes
compared with patients without diabetes (odds ratio 0.53, 95%
confidence interval 0.07 to 4.09). The incidence and 95%
confidence intervals for intraocular hemorrhage in patients
with and without diabetes are shown in Table 3. Table 4 shows
the age, gender, allocated thrombolytic regimen, location of
ocular hemorrhage and diabetic history for the 12 patients with
ocular hemorrhage.
There were 6,011 patients (15%) with a history of diabetes,
of whom 5,995 had information about ocular bleeding compli-
cations. Only one patient with diabetes had an ocular hemor-
rhage, and this was not an intraocular hemorrhage. Rather, it
Abbreviations and Acronyms
ACC/AHA 5 American College of Cardiology/American
Heart Association
GUSTO-I 5 Global Utilization of Streptokinase and t-PA
for Occluded Coronary Arteries (trial)
TAMI 5 Thrombolysis and Angioplasty in Myocardial
Infarction (trial)
Table 1. Baseline Characteristics of Patients With and Without
Ocular Hemorrhage
Patients With
Ocular
Hemorrhage
(n 5 12)
Patients Without
Ocular
Hemorrhage
(n 5 40,877)
Age (yr) 66 (47, 72) 62 (52, 70)
Male 9 (75.0) 30,580 (74.8)
Female 3 (25.0) 10,286 (25.2)
Killip class
I 11 (91.7) 34,734 (85.4)
II 1 (8.3) 5110 (12.6)
III 0 (0.0) 545 (1.3)
IV 0 (0.0) 308 (0.8)
Infarct location
Anterior 4 (33.3) 15,911 (39.0)
Inferior 8 (66.7) 23,447 (57.5)
Other 0 (0.0) 1346 (3.3)
None 0 (0.0) 50 (0.1)
Systolic blood pressure (mm Hg) 140 (113, 163) 130 (112, 144)
Heart rate (beats/min) 81 (74, 90) 74 (62, 86)
History of hypertension 2 (16.7) 15,513 (38.1)
Diabetes mellitus 1 (8.3) 5994 (14.7)
Data presented are number (%) of patients or median (25th, 75th percen-
tiles).
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was a soft tissue extraocular (eyelid) hematoma secondary to a
documented fall. The duration of the diagnosis of diabetes
mellitus and history of insulin therapy at the time of enroll-
ment were known for 4,105 patients (68%) with diabetes
enrolled in the GUSTO-I trial (Table 5).
Discussion
The results presented here from the GUSTO-I trial indicate
that ocular hemorrhage was a rare complication after throm-
bolytic therapy for acute myocardial infarction. There were
only 12 patients (0.03%) with ocular hemorrhage and, more
important, only 1 patient without diabetes had confirmed
intraocular hemorrhage. None of 6,011 patients with diabetes
had a clinically recognized intraocular hemorrhage. The one
diabetic patient with an ocular hemorrhage had an extraocular
(eyelid) hematoma after a documented fall. The upper 95%
confidence interval for the incidence of intraocular hemor-
rhage in patients with diabetes was 0.05%. These data suggest
that diabetic retinopathy should not be a contraindication to
thrombolytic therapy for acute myocardial infarction. Others
(6,7) also support this recommendation from their institutional
experiences. In addition, the newly published American Col-
lege of Cardiology/American Heart Association (ACC/AHA)
guidelines for management of patients with acute myocardial
infarction (8) no longer list diabetic hemorrhagic retinopathy
as a contraindication to thrombolysis.
Patients with diabetes are at an increased risk for coronary
artery disease and have a worse clinical outcome after acute
myocardial infarction than patients without diabetes (9–11).
Despite the significant survival benefit associated with throm-
bolytic therapy for these patients (12,13), they are often
excluded from such treatment (14). Although the reason for
this exclusion is not entirely clear, it may relate to the increased
age of these patients, longer delays in seeking medical atten-
tion or a higher incidence of concomitant medical problems,
such as diabetic retinopathy.
Diabetic retinopathy. The term diabetic hemorrhagic reti-
nopathy, used by Gunnar et al. (1) in the previous ACC/AHA
guidelines for management of patients with acute myocardial
infarction, is imprecise. Most ophthalmologists describe dia-
betic retinopathy as either nonproliferative (background) or
proliferative (15). Nonproliferative retinopathy classically in-
cludes retinal microaneurysms and retinal blot hemorrhages in
which blood is contained within retinal extracellular spaces.
Vitreous hemorrhage is not included in the classification of
nonproliferative retinopathy. Eyes with proliferative retinopa-
thy often demonstrate preretinal neovascularization but no
preretinal hemorrhage.
Vitreous hemorrhage in patients with diabetic retinopathy
is generally thought to result from posterior vitreous detach-
ment, which can cause traction on and damage to adherent
blood vessels (16,17). It is unclear how thrombolysis would
increase the risk for a detachment unless there was a recent
violation of the structural integrity of the microvasculature that
had an associated thrombus. Vitreous hemorrhage in a dia-
betic patient is not an irreversibly blinding event. Hemorrhage
often clears in patients with recovery of vision or can be
removed with vitreous surgery, allowing recovery of vision.
Previous reports. Fava et al. (18) retrospectively reviewed
data from 507 diabetic patients admitted to their institution
with an acute myocardial infarction. Fourteen patients had
documented nonproliferative retinopathy; no ocular hemor-
rhages were clinically recognized after treatment with throm-
bolytic therapy. However, 26 patients with a history of prolif-
erative diabetic retinopathy were not treated with thrombolysis.
A retrospective analysis (11) of clinical outcomes of dia-
betic patients after acute myocardial infarction studied the 158
patients (14%) with diabetes in the Thrombolysis and Angio-
plasty in Myocardial Infarction (TAMI) trials, which evaluated
various thrombolytic regimens and interventional strategies in
patients with an acute myocardial infarction. Eleven patients
(7%) had a history of diabetic retinopathy, and no clinically
evident intraocular hemorrhagic complications were recog-
nized. The GUSTO-I trial had fewer exclusion criteria than the
TAMI trials; as a large, simple, multicenter trial, it included a
population at higher risk and more representative of the
general acute myocardial infarction population. The median
patient age was higher in the GUSTO-I population than the
TAMI population (62 vs. 56 years). The effect of this increased
age in the GUSTO-I trial on ocular hemorrhage is unknown.
Several investigators (19) have studied the association
between the development of diabetic retinopathy and the age
at diagnosis of diabetes, the duration of diabetes and the need
Table 3. Incidence and Confidence Intervals for Intraocular
Hemorrhage in Patients With and Without Diabetes in the
GUSTO-I Trial
Diabetes
(n 5 5,995)
No Diabetes
(n 5 34,818)
Incidence 0 (0%) 1 (0.003%)*
95% CI 0.0–0.05 0.0–0.006
*Odds ratio and 95% confidence interval (CI) for intraocular hemorrhage in
patients with versus without diabetes (0.52, 0.02 to 12.68).
Table 2. Location of Ocular Hemorrhages in GUSTO-I Trial
(n 5 40,889)
Location
Number of Patients
Diabetes No Diabetes Total
Extraocular
Periorbital hematoma 1 3 4
Subconjunctival hemorrhage 0 7 7
Intraocular
Retinal hemorrhage 0 1 1
Vitreal hemorrhage 0 0 0
Total 1 11 12 (0.03%)
OR* 0.53
95% CI* 0.07–4.09
*Odds ratio (OR) and 95% confidence interval (CI) for incidence of ocular
hemorrhage in patients with versus without diabetes.
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for insulin therapy. Data on the duration of diabetes and
insulin therapy were available for patients in the GUSTO-I
trial. By applying these relations to the diabetic population in
GUSTO-I, we estimate that ;2,000 patients may have had
nonproliferative retinopathy, and ;300 could have had prolif-
erative retinal changes.
Outcome after ocular hemorrhage. Outcome after intraoc-
ular hemorrhage associated with thrombolytic therapy is un-
known. Data on visual deficits at the time of ocular hemor-
rhage and follow-up at hospital discharge were known for 9
GUSTO-I patients (75%) with ocular hemorrhage. Only the
patient with the choroidal (subretinal) hemorrhage had a
documented visual deficit that improved dramatically but was
still present at the time of hospital discharge. Others (20,21)
have reported that three patients with anterior chamber in-
traocular hemorrhage after thrombolytic therapy for acute
myocardial infarction within 8 days of cataract extraction had
no limitation in visual acuity at follow-up. Some argue (22) that
in the setting of thrombolytic and antiplatelet therapy, there
may be improved resolution of an intraocular hemorrhage. In
addition, the use of antiplatelet agents such as aspirin has been
questioned in patients with diabetes, but the Early Treatment
Diabetic Retinopathy Study (ETDRS) (23) investigators re-
ported no increase in the occurrence or severity of vitreous or
preretinal hemorrhages in patients with diabetes.
Diagnosis of retinopathy. The diagnosis of retinopathy is
often difficult in the emergency setting of an acute myocardial
infarction. Opiates may have been administered; patients may
be unable to fully cooperate with a fundal examination; and
although many patients with diabetes may have had a previous
detailed funduscopic examination, medical records may not be
available at the time that decisions have to be made about
administration of thrombolytic therapy. In addition, without a
complete fundus examination, significant diabetic retinopathy
will be missed. In two studies (24,25) comparing examination
with and without dilation of the pupil, diabetic retinopathy was
correctly identified in only 50% of eyes. Excluding diabetic
patients from thrombolysis because of a concern about the
possibility of retinopathy could potentially withhold life-saving
therapy from an important group of patients.
Limitations of the study. There are several limitations to
this study. The small number of ocular hemorrhages limits the
ability to determine factors statistically associated with such a
complication. However, the absolute numbers confirm that
there is indeed a very low risk for intraocular hemorrhage
associated with thrombolytic therapy.
There was no systematic assessment of all patients to
determine the incidence of diabetic retinopathy; therefore, the
precise risk for ocular hemorrhage among patients with dia-
betic retinopathy treated with thrombolysis cannot be deter-
mined. However, it would have provided a better estimate of
the risks and benefits associated with thrombolytic therapy.
The estimated incidence of diabetic retinopathy in the
GUSTO-I population may have been affected by the exclusion
of diabetic patients from the trial. However, a reliable estimate
of the potential number of patients with diabetic retinopathy in
the GUSTO-I trial can be provided from analysis of the 4,112
patients with data about duration of diabetes and insulin
therapy requirements.
Table 4. Twelve Patients With Ocular Hemorrhage: Age, Gender, Treatment Assignment, Ocular
Hemorrhage Location and Diabetic History (GUSTO-I trial)
Pt No./Gender
Age
(yr) Treatment Ocular Hemorrhage Location Diabetic History
1/M 68 t-PA Right conjunctival None
2/M 49 t-PA Bilateral conjunctival None
3/F 74 Combo Eyelid (after documented fall) 13-yr history; not taking insulin
4/F 66 Combo Right choroidal (subretinal) None
5/F 66 t-PA Periorbital None
6/M 72 Combo Periorbital None
7/M 56 Combo Right conjunctival None
8/M 34 SK1SQ Bilateral conjunctival None
9/M 34 SK1IV Bilateral scleral None
10/M 72 Combo Periorbital (after documented fall) None
11/M 76 Combo Left conjunctival None
12/M 44 SK1SQ Left conjunctival None
Combo 5 combination therapy with streptokinase (SK) and tissue-type plasminogen activator (t-PA); F 5 female;
IV 5 intravenous heparin; M 5 male; Pt 5 patient; SQ 5 subcutaneous heparin.
Table 5. Duration of Diagnosis of Diabetes Mellitus and History of
Insulin Therapy in Patients With Diabetes in GUSTO-I
Duration of
Diagnosis (yr) No. of Pts
Insulin Therapy
[no. (%) of pts]
,10 2,490 450 (18.1)
10–14 681 260 (38.2)
15–19 390 190 (48.7)
.20 551 296 (53.7)
Unknown 1,899 447 (24.3)
Total 6,011 1,643 (27.3)
Pts 5 patients.
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Many patients with diabetes or with diabetic retinopathy
may have been excluded from enrollment in GUSTO-I, al-
though the protocol did not indicate that such patients should
not be enrolled. The reason for study exclusion was not
documented for all patients considered for enrollment in the
GUSTO-I trial.
Finally, the incidence of unrecognized intraocular hemor-
rhage, and its associated long-term consequences, is not
known.
Conclusions. Ocular hemorrhage and, more important,
intraocular hemorrhage after thrombolytic therapy for acute
myocardial infarction, is extremely uncommon. In the
GUSTO-I trial there were 12 ocular hemorrhages (0.03%),
only 1 of which was an intraocular hemorrhage. No patient
with diabetes had an intraocular hemorrhage despite an esti-
mated 2,000 diabetic patients with nonproliferative retinopathy
and 300 with proliferative retinopathy. The calculated upper
95% confidence interval of 0.05% for the incidence of intraoc-
ular hemorrhage in patients with diabetes in the GUSTO-I
population is small and probably negligible compared with the
proven life-saving benefit associated with thrombolysis for
acute myocardial infarction in these patients. Excluding pa-
tients with diabetes because of a potentially increased risk for
intraocular hemorrhage is not supported by our data. We
conclude that diabetic retinopathy should not be considered a
contraindication to the administration of thrombolytic therapy
in patients with acute myocardial infarction.
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